Aspartate aminotransferase-to-platelet ratio index for predicting late recurrence of hepatocellular carcinoma after radiofrequency ablation

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Zhang SS, Zheng RS, Zeng HM, et al. Cancer incidence and mortality in China, 2015. JNCC. 2021;1(1):2–11.
   Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589–604.
   PubMed Web of Science ®Google Scholar
• Mulier S, Ni Y, Jamart J, et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158–171.
   PubMed Web of Science ®Google Scholar
• Ogihara M, Wong LL, Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB. 2005;7(3):214–221.
   PubMedGoogle Scholar
• Sugo H, Ishizaki Y, Yoshimoto J, et al. Salvage hepatectomy for local recurrent hepatocellular carcinoma after ablation therapy. Ann Surg Oncol. 2012;19(7):2238–2245.
   PubMed Web of Science ®Google Scholar
• Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2019;1154(3):209–217.
   PubMed Web of Science ®Google Scholar
• Zheng J, Chou JF, Gönen M, et al. Prediction of hepatocellular carcinoma recurrence beyond milan criteria after resection: validation of a clinical risk score in an international cohort. Ann Surg. 2017;266(4):693–701.
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Ikoma H, Morimura R, et al. Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. WJG. 2015;21(4):1207–1215.
   PubMed Web of Science ®Google Scholar
• Lin C, Lin C, Wang C, et al. The ALBI grade is a good predictive model for very late recurrence in patients with hepatocellular carcinoma undergoing primary resection. World J Surg. 2020;44(1):247–257.
   PubMed Web of Science ®Google Scholar
• Chok K, Chan S, Cheung T, et al. Late recurrence of hepatocellular carcinoma after liver transplantation. World J Surg. 2011;35(9):2058–2062.
   PubMed Web of Science ®Google Scholar
• Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(4):782–789.e4.
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Brouwer WP, Chan HL, et al. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. Lancet Gastroenterol Hepatol. 2019;4(7):538–544.
   PubMed Web of Science ®Google Scholar
• Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486–1501.
   PubMed Web of Science ®Google Scholar
• Lai L, Su T, Liang Z, et al. Development and assessment of novel predictive nomograms based on APRI for hepatitis B virus-associated small solitary hepatocellular carcinoma with stereotactic body radiotherapy. J Cancer. 2020;11(22):6642–6652.
   PubMed Web of Science ®Google Scholar
• Maegawa FB, Shehorn L, Aziz H, et al. Association between noninvasive fibrosis markers and postoperative mortality after hepatectomy for hepatocellular carcinoma. JAMA Netw Open. 2019;2(1):e187142.
   PubMed Web of Science ®Google Scholar
• Zhang TT, Ye SS, Liang J, et al. Prognostic value of non-invasive fibrosis indices post-curative resection in hepatitis-B-associated hepatocellular carcinoma patients. Exp Biol Med. 2020;245(8):703–710.
   Web of Science ®Google Scholar
• Zhu GQ, Wang K, Wang B, et al. Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization. CMAR. 2018;11:63–79.
   Web of Science ®Google Scholar
• EASL-EORTC Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Huo J, Aloia TA, Xu Y, et al. Comparative effectiveness of computed tomography- versus ultrasound-guided percutaneous radiofrequency ablation among medicare patients 65 years of age or older with hepatocellular carcinoma. Value Health. 2019;22(3):284–292.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Do KG, et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Intervent Radiol. 2018;29(2):268–275.e1.
   PubMed Web of Science ®Google Scholar
• Puijk RS, Ahmed M, Adam A, et al. Consensus guidelines for the definition of time-to-Event end points in image-guided tumor ablation: results of the SIO and DATECAN Initiative. Radiology. 2021;301(3):533–540.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria – a 10-year update. Radiology. 2014;273(1):241–260.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259.
   PubMed Web of Science ®Google Scholar
• Wang MD, Li C, Liang L, et al. Early and late recurrence of hepatitis B virus-associated hepatocellular carcinoma. Oncologist. 2020;25(10):e1541–e1551.
   PubMed Web of Science ®Google Scholar
• Kao WY, Chiou YY, Hung HH, et al. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index. Eur J Gastroenterol Hepatol. 2011; Jun23(6):528–536.
   PubMed Web of Science ®Google Scholar
• Chung HA, Kim JH, Hwang Y, et al. Noninvasive fibrosis marker can predict recurrence of hepatocellular carcinoma after radiofrequency ablation. Saudi J Gastroenterol. 2016;22(1):57.
   PubMed Web of Science ®Google Scholar
• Guo C, Liang H, Yuan W, et al. Analysis on the value of soluble intercellular adhesion molecule-1 (sICAM-1), alpha fetoprotein (AFP), and aspartate aminotransferase/platelet ratio index (APRI) in predicting the prognostic survival of patients with primary liver cancer after radiofrequency ablation. Ann Palliat Med. 2021;10(4):4760–4767.
   Google Scholar
• Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(Suppl 19):89–95.
   Google Scholar
• Ho-Tin-Noé B, Carbo C, Demers M, et al. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am J Pathol. 2009;175(4):1699–1708.
   PubMed Web of Science ®Google Scholar
• Placke T, Örgel M, Schaller M, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–448.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–2576.
   PubMed Web of Science ®Google Scholar
• White DL, Thrift AP, Kanwal F, et al. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology. 2017;152(4):812–820.e5.
   PubMed Web of Science ®Google Scholar
• Ho PH, Teng W, Lin CC, et al. Prolonged post-ablation fever may predict one-year tumor recurrence in hepatocellular carcinoma after radiofrequency ablation. Int J Hyperthermia. 2020;37(1):1008–1015.
   PubMed Web of Science ®Google Scholar